Advances in ovarian cancer drug therapy

• Gennady T. Sukhikh
• Ashrafyan Lev A.
• Kiselev Vsevolod I.
• Antonova Irina B.
• Gerfanova Evgenia V.
• Aleshikova Olga I.

Abstract

In the article modern concept of ovarian cancer (OC) carcinogenesis are represented. Its main key points are cancer stem cells, consistency of the process and inflammation. Pharmacy development and appearance of drugs that can simultaneously affect many targets of a tumor cell (multitarget effect), indirectly affecting its microenvironment, with a limited number of side effects, makes it possible to look at ovarian cancer therapy with great optimism in the near future.

The aim of the study was to increase effectiveness of standard combination therapy for patients with OC by including into background therapy regimen multi-target drugs containing indole-3-carbinol and a combination of indole-3-carbinol with epigallocatechin-3-gallate (Promisan®).

Material and methods. 284 patients participated in the study. All of them were examined and treated for ascites forms of serous OC.

Results and conclusions. Administration of indole-3-carbinol and combination of indole-3-carbinol with epigallocatechin-3-gallate (Promisan®) in addition to standard combination therapy of OC increased its effectiveness by creating conditions for achieving longer relapse-free and overall longevity.

Keywords:ovarian cancer, tumor stem cell, inflammation, ascites, indole-3-carbinol, epigallocatechin-3-gallate

References

1. Ferlay J., Colombet M., Soerjomataram I., Mathers C. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods // Int. J. Cancer. 2018 Oct 23. doi: 10.1002/ijc.31937. PubMed PMID: 30350310.

2. American Cancer Society. Cancer Facts and Figures 2019. Global Headquarters. Atlanta : American Cancer Society Inc., 2019. URL: www.cancer.org/

3. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: FGBU "MNIOI im. P.A. Gertsena" Minzdrava Rossii, 2018. 250 p. (in Russian)

4. Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012 Moscow: IG RONTS, 2014. 175 p. (in Russian)

5. Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer. 2017; 16 (1): 64. URL: https://doi.org/10.1186/s12943-017-0638-3 .

6. Ahmed N., Abubaker K., Findlay J., et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013; 114 (1): 21-34.

7. Walters Haygood C.L., Arend R.C., Straughn J.M., et al. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells. 2014; 6 (4): 441-7.

8. Kipps E., Tan D.S., Kaye S.B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013; 13 (4): 273-82.

9. Mo L., Pospichalova V., Huang Z. Ascites increases expression/ function of multidrug resistance proteins in ovarian cancer cell. PloS One. 2015; 10 (7). doi. 10.1371/journal.pone.0131579.

10. Ahmed N., Abubaker K., Findlay J.K. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Mol Aspects Med. 2013; 39: 110-25. doi: 10.1016/j.mam.2013.06.002.

11. Ricci F., Guffanti F., Damia G., et al. Ovarian cancer recurrence: role of ovarian stem cells and epithelial-to-mesenchymal transition. J Cancer Sci Ther. 2014; 6: 298-305. doi: 10.4172/1948-5956.1000284.

12. Ottevanger P.B. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 2017; 14: 67-71.

13. Foster R., Buckanovich R.J., Rueda B.R. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2013; 338 (1): 147-57.

14. Zhan Q., Wang C., Ngai S. Ovarian cancer stem cells: a new target for cancer therapy // Biomed. Res. Int. 2013. Vol. 2013. Article ID 916819.

15. Kwon M.J., Shin Y.K. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 2013; 14: 6624-48.

16. Banerjee S., Kong D., Wang Z., et al. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinicio Mutat. Res. 2011; 728: 47-66.

17. Gu J.W., Makey K.L., Tucker K.B., et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1a and NFkB, and VEGF expression. Vasc Cell. 2013; 5 (1): 9. doi: 10.1186/2045-824X-5-9.

18. Khan N., Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008; 269 (2): 269-80.

19. Johnson R., Bryant S., Huntley A.L. Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas. 2012; 73 (4): 280-7.

20. Kandala P.K., Srivastava S.K. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT 3) // BMC Med. 2012. Vol. 10. P. 9.

21. Kandala P.K., Srivastava S.K. DIMming ovarian cancer growth // Curr. Drug Targets. 2012. Vol. 13. P. 1869-1875.

22. Kandala P.K., Srivastava S.K. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget. 2012; 3 (4): 435-49.

23. Zou M., Xu C., Li H. 3,3'-Diindolylmethane suppresses ovarian cancer cell viability and metastasis and enhances chemotherapy sensitivity via STAT3 and Akt signaling in vitro and in vivo. Arch Biochem Biophys. 2018 July. doi: 10.1016/j.abb.2018.07.002.

24. Trudel D., Labbe D.P., Bairati I., et al.Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecol Oncol. 2012; 126 (3): 91-8.

25. Chen D., Banerjee S., Cui1 Q.C., et al. Activation of AMP-activated protein kinase by 3,3'-diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One. 2012; 7 (10). Article ID e47186.

26. Semov A., Iourtchenco L., Liu L.F., et al. Diindolylmethane (DIM) selectively inhibits cancer stem cells. Biochem BiophysRes Commun. 2012; 424: 45-51.

27. Gen R.-Y., Li H.-B., Si Z.-Q., et al. Absorption, metabolism, anticancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review. Crit Rev Food Sci Nutr. 2018; 58 (6): 924-41.

28. Kumazoe M., Takai M., Hiroi S., et al. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7: 1917. doi: 10.1038/s41598-017-02162-9.

29. Rady I., Mohamed H., Rady M., et al.Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. Egypt J Basic Appl Sci. 2018; 5: 1-23.

30. Toden S., Tran H.M., Tovar-Camargo O.A., et al Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016; 7 (13): 16 158-71.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)